What is the treatment for Campylobacter and Escherichia coli (E. coli) infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Campylobacter and E. coli Infections

Azithromycin is the first-line treatment for Campylobacter infections due to increasing fluoroquinolone resistance worldwide, while antimicrobial therapy for E. coli infections depends on the specific strain and severity of illness. 1

Treatment for Campylobacter Infections

First-Line Therapy

  • Azithromycin:
    • Adults: 500 mg once daily for 3 days or a single 1-gram dose
    • Children: 20-30 mg/kg as a single dose 1
    • Most effective when started within 72 hours of symptom onset
    • All Campylobacter isolates have shown susceptibility to azithromycin in studies 2

Alternative Treatments (in areas with low fluoroquinolone resistance)

  • Ciprofloxacin 500 mg twice daily for 3 days 1, 3
  • Levofloxacin 500 mg once daily for 3 days 1

Important Considerations

  • Fluoroquinolone resistance in Campylobacter is increasing worldwide (>10.2% in Minnesota) 4
  • Quinolone resistance can develop during treatment and lead to symptomatic relapse 4
  • Antibiotic treatment shortens the duration of illness by approximately 1.32 days 5
  • In rare cases of macrolide and fluoroquinolone resistance, fosfomycin-tromethamine may be considered as an alternative 6

Treatment for E. coli Infections

Enterotoxigenic E. coli (ETEC)

  • Ciprofloxacin is FDA-approved for infectious diarrhea caused by enterotoxigenic E. coli 3
  • Trimethoprim-sulfamethoxazole (TMP-SMZ) is indicated for traveler's diarrhea due to enterotoxigenic E. coli 7

Shiga Toxin-Producing E. coli (STEC)

  • Antibiotics should NOT be used for suspected or documented STEC infections 4, 1
  • Antimotility agents should also be avoided 4
  • Antibiotic treatment may increase the risk of hemolytic uremic syndrome (HUS) 4, 1

General Approach to Treatment

Indications for Antimicrobial Therapy

  1. Severe symptoms
  2. Immunocompromised hosts
  3. Persistent symptoms
  4. Dysentery (bloody diarrhea)
  5. Systemic spread of infection 1

Supportive Care (First-Line for All Patients)

  • Oral rehydration solution (ORS) for mild to moderate dehydration 1
  • Continue age-appropriate diet during or immediately after rehydration 1
  • IV fluids for severe dehydration

Treatment Algorithm

  1. Assess severity: Determine if patient has mild, moderate, or severe illness
  2. Identify pathogen if possible: Stool culture to differentiate Campylobacter from E. coli
  3. For Campylobacter:
    • Start azithromycin if indicated
    • Monitor for clinical response
  4. For E. coli:
    • If ETEC: Consider ciprofloxacin or TMP-SMZ
    • If STEC or suspected STEC: Avoid antibiotics and antimotility agents
    • If other E. coli strains: Treat based on susceptibility testing

Prevention and Follow-up

  • Proper hand hygiene after using the toilet and before preparing or eating food 1
  • Avoid raw or undercooked poultry, meat, and unpasteurized dairy products 1
  • Monitor for worsening symptoms, signs of dehydration, and response to treatment 1
  • Consider non-infectious conditions if symptoms persist beyond 14 days 1

Important Caveats

  • Antibiotics should not be prescribed simply to reduce secondary transmission 4
  • Overuse of antibiotics can lead to emergence of resistant strains 8
  • Quinolone resistance in Campylobacter is a growing concern globally 4, 9
  • Delayed treatment in immunocompromised patients should be avoided 1

References

Guideline

Management of Campylobacter Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007

Research

New and alternative strategies for the prevention, control, and treatment of antibiotic-resistant Campylobacter.

Translational research : the journal of laboratory and clinical medicine, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.